Principally, there are three different categories for the determining HRD:Next-generation sequencing (NGS) assays: These assays analyze genomic DNA to detect mutations in genes associated with HRD, such as BRCA1 and BRCA2, as well as other HRD-related genes.Genetic Testing: mutations in the BRCA1 and BRCA2 genes are well-established indicators of HRD, particularly in breast and ovarian cancers. This evidence concerns the gene BRCA1 and ovarian carcinoma.